Successful Treatment with Infliximab for Refractory Uveitis in a Hemodialysis Patient with Behcet's Disease and a Review of the Literature for Infliximab Use in Patients on Hemodialysis

A 36-year-old man with a 16-year history of refractory Behcet's disease (BD)-associated uveitis and chronic renal failure requiring hemodialysis suffered from frequent ocular attacks despite treatment with systemic corticosteroids and cyclosporine A. Following infliximab administration, the patient's BD ocular attack score 24 and visual acuity improved. Although he developed mild acute gastroenteritis, he did not experience any other adverse events. In our review of the literature, we identified seven patients on hemodialysis with inflammatory disease successfully treated with infliximab. Infliximab may be effective and safe in cases of BD and other diseases, including in patients under hemodialysis.